Differential Effects of Complement Activation Products C3a and C5a on Cardiovascular Function in Hypertensive Pregnant Rats

Kathryn E. Lillegard, Alex C. Loeks-Johnson, Jonathan W. Opacich, Jenna M. Peterson, Ashley J. Bauer, Barbara J. Elmqquist, Ronald R. Regal, Jeffrey S. Gilbert, and Jean F. Regal

Department of Biomedical Sciences, University of Minnesota Medical School Duluth (K.E.L., A.C.L.-J., J.W.O., J.M.P., A.J.B., B.J.E., J.S.G., J.F.R.) and Department of Mathematics and Statistics, University of Minnesota Duluth (R.R.R.), Duluth, Minnesota

Received July 21, 2014; accepted August 21, 2014

ABSTRACT

Early-onset pre-eclampsia is characterized by decreased placental perfusion, new-onset hypertension, angiogenic imbalance, and endothelial dysfunction associated with excessive activation of the innate immune complement system. Although our previous studies demonstrated that inhibition of complement activation attenuates placental ischemia–induced hypertension using the rat reduced uterine perfusion pressure (RUPP) model, the important product(s) of complement activation has yet to be identified. We hypothesized that antagonism of receptors for complement activation products C3a and C5a would improve vascular function and attenuate RUPP hypertension. On gestational day (GD) 14, rats underwent sham surgery or vascular clip placement on ovarian arteries and abdominal aorta (RUPP). Rats were treated once daily with the C5a receptor antagonist (C5aRA), PMX51 (acetyl-F-[Orn-P-(D-Cha)-WR]), the C3a receptor antagonist (C3aRA), SB290157 (N\(^2\)-(2,2-diphenylethoxy)acetyl]-L-arginine), or vehicle from GD 14–18. Both the C3aRA and C5aRA attenuated placental ischemia–induced hypertension without affecting the decreased fetal weight or decreased concentration of free circulating vascular endothelial growth factor (VEGF) also present in this model. The C5aRA, but not the C3aRA, attenuated placental ischemia–induced increase in heart rate and impaired endothelial-dependent relaxation. The C3aRA abrogated the acute pressor response to C3a peptide injection, but it also unexpectedly attenuated the placental ischemia–induced increase in C3a, suggesting nonreceptor-mediated effects. Overall, these results indicate that both C3a and C5a are important products of complement activation that mediate the hypertension regardless of the reduction in free plasma VEGF. The mechanism by which C3a contributes to placental ischemia–induced hypertension appears to be distinct from that of C5a, and management of pregnancy-induced hypertension is likely to require a broad anti-inflammatory approach.

Introduction

Pre-eclampsia is a pregnancy-specific condition characterized by decreased placental perfusion, new-onset hypertension, intrauterine growth restriction, and endothelial dysfunction. Affecting up to 10% of pregnancies in the United States, pre-eclampsia and hypertensive disorders of pregnancy are a leading cause of maternal and perinatal morbidity and mortality with few effective treatment options (American College of Obstetricians and Gynecologists, 2013; Ananth et al., 2013). The complement system, part of the innate immune response, is an enzymatic amplification system composed of plasma proteins essential for host defense and inflammation. The complement system can be activated by multiple pathways, with a central event being formation of the enzyme C3 convertase, which cleaves C3 to generate fluid-phase C3a as well as C3b, which covalently binds to an invader or self, i.e., C3 deposition (Fig. 1). C3b serves as a nucleus for formation of C5 convertase, which cleaves C5 to generate fluid-phase C5a, which activates the complement cascade. The C5a receptor antagonist (C5aRA) attenuates placental ischemia-induced hypertension in rat (Abstract). FASEB J 28:1084.7; Opacich JW, Johnson AC, Bauer AJ, Gilbert JS, and Regal JF (2014) Antagonism of complement C5a receptor but not C3a receptor attenuates placental ischemia-induced endothelial dysfunction in rat (Abstract). FASEB J 28:1084.8; and Regal JF, Lillegard KE, Elmqquist BJ, Bauer AJ, Johnson AC, Opacich JW, Peterson JM, and Gilbert JS (2013) Complement C3a receptor antagonist attenuates placental ischemia-induced hypertension in rat (Abstract). Hypertension 62:A10.

Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2014/08/22/jpet.114.218123.DC1

This article has supplemental material available at jpet.aspetjournals.org.
preterm labor, and pre-eclampsia (Lynch and Salmon, 2010). During pregnancies complicated with pre-eclampsia, there is strong evidence of excessive complement activation in the circulation, with a decrease in C3 concentration and an increase in C5a, soluble C5b-9, and the ratio of C3a to C3 (Derzsy et al., 2010; Soto et al., 2010), as well as excessive complement activation in placenta (Buurma et al., 2012; Gilbert et al., 2012c) and urine (Burwick et al., 2013). A recent case report suggests that complement contributes to pre-eclamptic symptoms because depletion of complement component C5 in a severely pre-eclamptic woman was able to prolong pregnancy by >2 weeks (Burwick and Feinberg, 2013).

Mechanistic studies in clinically relevant animal models are clearly needed to identify critical products of complement activation contributing to pre-eclamptic symptoms. Using the reduced uterine perfusion pressure (RUPP) rat model of placental ischemia–induced hypertension and soluble complement receptor 1 as an inhibitor of complement activation, our studies were the first to describe a link between complement system activation and the hypertension resulting from third-trimester placental ischemia in pregnancy (Lillegard et al., 2013b). We also demonstrated that angiogenic imbalance as well as impaired endothelial-dependent relaxation in isolated blood vessels occur in this model (Gilbert et al., 2010).

Inhibiting complement activation attenuated hypertension in the RUPP model, but angiogenic imbalance, i.e., decreased vascular endothelial growth factor (VEGF), was still evident, suggesting that the role of complement in placental ischemia–induced hypertension was independent of VEGF. Complement activation products C3a and C5a were potent (~10-kDa) fluid-phase inflammatory mediators that interact with G protein–coupled receptors on many cell types to elicit biologic activities including smooth muscle contraction and changes in blood pressure (Regal et al., 1980; Regal, 1982; Proctor et al., 2009), activation and chemotaxis of immune cells, and increased vascular permeability (Klos et al., 2013). In addition, excessive complement activation can adversely affect endothelial function (Collard et al., 2000). With the realization of the importance of immune inflammatory pathways in numerous disease states, C3a and C5a receptor antagonists are being developed for potential clinical use and have also been used in numerous animal models to investigate the role of C3a and C5a in disease models (Ricklin and Lambris, 2013). Using antagonists of the C3a and C5a receptors, the present study is the first to test the hypothesis that C3a and C5a are the complement activation products that mediate endothelial dysfunction and hypertension following placental ischemia.

**Materials and Methods**

**RUPP Procedure and Antagonist Administration.** The RUPP procedure was performed on gestational day (GD) 14 to achieve chronic placental ischemia and hypertension in pregnant rats on GD 19 (see Supplemental Methods for details) (Lillegard et al., 2013b). All animal experiments were approved by the University of Minnesota Institutional Animal Care and Use Committee and conformed to the National Institutes of Health Guide for Care and Use of Laboratory Animals. Animals were treated with either the C3a receptor antagonist (C3aRA), SB290157 (N²-[2,2-diphenylethoxy]acetyl)-L-arginine; Merck KGaA, Darmstadt, Germany) (Ames et al., 2005), at 5 mg/kg i.v.; the C5a receptor antagonist (C5aRA), PMX53 (acetyl-F-[Orn-P-(D-Cha)-WR]; synthesized by Atlantic Peptides, Lewisburg, PA) (Finch et al., 1999), at 3 mg/kg s.c., or 10% ethanol/saline vehicle (Veh). Once-daily treatments began 10–15 minutes before RUPP or sham surgery on GD 14 and ended on GD 18. Animals were randomly assigned to the following treatment groups: 1) RUPP surgery with intravenous Veh; 2) RUPP surgery with subcutaneous Veh; 3) RUPP surgery with C3aRA (RUPP C3aRA); 4) RUPP surgery with C5aRA (RUPP C5aRA); 5) RUPP surgery with C3aRA and C5aRA; 6) sham surgery with intravenous Veh; 7) sham surgery with subcutaneous Veh; 8) sham surgery with C3aRA (Sham C3aRA); or 9) sham surgery with C5aRA (Sham C5aRA). The vehicle for both antagonists was 10% ethanol/saline and was administered either intravenously or subcutaneously. With statistical analysis, no differences in outcomes were detected with administration of Veh by either the subcutaneous or intravenous route, so groups 1 (n = 10) and 2 (n = 13) were combined as Sham Veh and groups 3, 6 (n = 10) and 7 (n = 9) combined as Sham Veh in the final data presentation and analysis.

**Mean Arterial Pressure Measurements and Tissue Collection.** Mean arterial pressure (MAP) and heart rate were measured via intra-arterial catheter in unanesthetized, restrained animals on GD 19, and serum, plasma, and fetal and placental tissue were harvested as described previously (Lillegard et al., 2013b). Circulating white blood cells (WBCs) in EDTA blood were counted by standard methods in intra-arterial catheter in unanesthetized, restrained animals on GD 19, –15 minutes before RUPP or sham surgery (Sham) on GD 14 and ended on GD 18. Animals were randomly assigned to the following treatment groups: 1) RUPP surgery with intravenous Veh; 2) RUPP surgery with subcutaneous Veh; 3) RUPP surgery with C3aRA (RUPP C3aRA); 4) RUPP surgery with C5aRA (RUPP C5aRA); 5) RUPP surgery with C3aRA and C5aRA; 6) sham surgery with intravenous Veh; 7) sham surgery with subcutaneous Veh; 8) sham surgery with C3aRA (Sham C3aRA); or 9) sham surgery with C5aRA (Sham C5aRA). The vehicle for both antagonists was 10% ethanol/saline and was administered either intravenously or subcutaneously. With statistical analysis, no differences in outcomes were detected with administration of Veh by either the subcutaneous or intravenous route, so groups 1 (n = 10) and 2 (n = 13) were combined as Sham Veh and groups 3, 6 (n = 10) and 7 (n = 9) combined as Sham Veh in the final data presentation and analysis.
Results
Receptor Antagonists Attenuate Placental Ischemia–Induced Hypertension. To determine if the complement activation products C3a and/or C5a were important in mediating placental ischemia-induced hypertension, we evaluated the effect of treatment with C3aRA or C5aRA. Chronic placental ischemia caused a significant increase in MAP by GD 19 (Fig. 2A). Clearly, treatment with either the C3aRA or C5aRA significantly inhibited RUPP-induced increase in MAP without altering MAP in Sham animals. Treatment of animals with a combination of C3aRA and the C5aRA did not result in greater attenuation of MAP than treatment with either antagonist alone (104 ± 3 mm Hg; n = 9; data not shown). As seen in Fig. 2B, heart rate in RUPP rats was increased as previously described (Gilbert et al., 2012e) and was significantly decreased by treatment with the C5aRA (P < 0.05) but not the C3aRA (P = 0.11).

Placental Ischemia–Induced Decrease in Free Plasma VEGF, Fetal Weight, and Resorptions Is Unaffected by Receptor Antagonists. As previously shown, placental ischemia resulted in decreased free plasma VEGF (Fig. 3A) and intrauterine growth restriction in RUPP compared with Sham controls (Fig. 3B). Treatment with either the C3aRA or C5aRA did not alter VEGF or fetal weight in RUPP rats (Fig. 3). Combined treatment with both antagonists (n = 9) also did not affect RUPP-induced decrease in either outcome (fetal weight, 2.1 ± 0.8 g; VEGF, 1679 ± 220 pg/ml). Antagonist treatment of Sham animals did not significantly alter circulating free plasma VEGF or fetal weight compared with Sham Veh animals. As previously reported, no increase in soluble fms-like tyrosine kinase-1 (soluble VEGF receptor 1), as measured by the commercially available mouse kit from R&D Systems, was detected in EDTA plasma collected on GD 19 from RUPP versus Sham animals in our experiments (Lillegard et al., 2013b). In addition, a significant increase in protein in urine was also not detected between RUPP and Sham animals in these studies, consistent with previous reports regarding the inconsistency of this measure in the RUPP model (Granger et al., 2006). Fetal resorptions were also assessed, and as previously shown (Lillegard et al., 2013b), RUPP surgery increased fetal resorptions (Supplemental Fig. 1). Treatment of RUPP or Sham animals with the C3aRA, the C5aRA, or the combination did not change the number of resorptions (Supplemental Fig. 1).
C3aRA, but Not C5aRA, Inhibits Increased C3a In Vivo Following Placental Ischemia. Relative serum C3a concentrations were used as an indicator of complement activation. Rat C5a was not detectable by current assay methods. The C3aRA and C5aRA were not expected to inhibit complement activation, but only antagonize actions of cleavage fragments C3a and C5a at their receptors. As seen in Fig. 4, our data confirm our previous studies (Lillegard et al., 2013b), demonstrating that RUPP significantly increases C3a in the circulation. Treatment with the C5aRA altered neither RUPP-induced increase in C3a nor baseline C3a concentration in Sham animals. Surprisingly, treatment with the C3aRA in vivo significantly inhibited C3a generation in both RUPP and Sham groups. CH50 measures the ability of the classical complement pathway components in serum to react sequentially and lyse the red blood cell coated with antibody. The receptor antagonists are not expected to affect CH50 because they prevent the action of C3a and C5a on their receptors without affecting activation of the complement cascade. Neither C3aRA nor C5aRA treatment in vivo, either alone or in combination, significantly affected total hemolytic complement activity (CH50; Supplemental Fig. 2), indicating that they were not inhibiting classical pathway complement activation or appreciably depleting total complement activity in vivo. In addition, in vitro studies demonstrated that incubating the C3aRA (390 μg/ml) or C5aRA (100 μg/ml) with normal rat serum did not inhibit the CH50 of the serum (data not shown), indicating that the antagonists were not altering classical hemolytic complement pathway activity in vitro.

C3aRA Inhibits C3a-Induced Pressor Response. Previous studies of others indicated differential vascular reactivity in pregnant versus nonpregnant rats (Paller, 1987). Thus, the ability of C3a to cause a pressor response in the pregnant rat was evaluated. An intravenous injection of 30 μg/kg C3a peptide in anesthetized pregnant dams on GD 19 resulted in a rapid transient pressor response within minutes (Fig. 5), similar to the response in nonpregnant rats of a comparable age and size. Injection of the C3aRA (100 μg/kg itself did not significantly alter MAP in nonpregnant or pregnant rats at GD 19 (Fig. 5), but it significantly inhibited the pressor response to 30 μg/kg C3a peptide in both nonpregnant and pregnant rats.

C5aRA Reduces Circulating Neutrophils. Because studies of Proctor et al. (2004) indicated that the C3aRA exhibits partial agonist activity and affects circulating neutrophils in the nonpregnant rat, we determined the effect of both the C3aRA and C5aRA on circulating WBCs. Although RUPP did not alter total WBCs and neutrophils in circulation, analysis of variance indicated that the C5aRA decreased circulating WBCs and neutrophils, regardless of Sham or RUPP surgery (Fig. 6). Chronic C3aRA administration had no significant effect on circulating WBCs or neutrophils. Total lymphocytes were not affected by RUPP surgery, C3aRA, or C5aRA (data not shown). Previous studies of others have clearly demonstrated an important role for lymphocytes in the RUPP model (LaMarca et al., 2013). However, our studies were not designed to detect changes in lymphocyte subpopulations. Analysis of neutrophils in the lung demonstrated that neutrophils were not being
C5a contracted the isolated rat mesenteric arteries (data not et al., 1985), but neither C3a peptide nor recombinant human including microvessels in the hamster cheek pouch (Bjork isolated blood vessels (Regal, 1982; Bjork et al., 1985), shown). Both C3a and C5a have been reported to contract with both the C3aRA and C5aRA affected Ach and SNP rats undergoing Sham Veh treatment. Combination treatment indicated by Ach-induced vasodilation equivalent to that seen in preserved endothelial function following placental ischemia, as ischemia (Supplemental Fig. 4). The C5aRA, but not the C3aRA, vasodilation in response to SNP was not affected by placental sequestered in the lung by any of the treatments (Supplemental Fig. 3).

C5aRA, but Not C3aRA, Attenuates Endothelial Dysfunction Following Placental Ischemia. As previously demonstrated in this model, vasodilation in response to Ach was attenuated in mesenteric arteries from rats with placental ischemia (Fig. 7). In contrast, endothelial-independent vasodilation in response to SNP was not affected by placental ischemia (Supplemental Fig. 4). The C5aRA, but not the C3aRA, preserved endothelial function following placental ischemia, as indicated by Ach-induced vasodilation equivalent to that seen in rats undergoing Sham Veh treatment. Combination treatment with both the C3aRA and C5aRA affected Ach and SNP relaxation in the same way as the C5aRA alone (data not shown). Both C3a and C5a have been reported to contract isolated blood vessels (Regal, 1982; Bjork et al., 1985), including microvessels in the hamster cheek pouch (Bjork et al., 1985), but neither C3a peptide nor recombinant human C5a contracted the isolated rat mesenteric arteries (data not shown). In addition, neither the C3aRA nor the C5aRA significantly relaxed isolated mesenteric arteries whether at normal resting tension or when precontracted with the thromboxane mimetic U46619.

Discussion

Using soluble complement receptor 1, an established inhibitor of complement activation, our previous studies demonstrated a critical role for complement activation in placental ischemia–induced hypertension in rat (Lillegard et al., 2013b), suggesting that manipulation of the complement system is a viable therapeutic strategy for management of pregnancy-induced hypertension. Given the importance of complement in host defense and immune complex clearance, defining specific product(s) of complement activation responsible for placental ischemia–induced hypertension is an important step toward defining therapeutic targets that minimally compromise the protective role of complement. Because complement activation products C3a and C5a are well known for their role as inflammatory mediators through interaction with G protein–coupled receptors on multiple cell types (Klos et al., 2013), we used receptor antagonists to assess the contribution of C3a and C5a to placental ischemia–induced hypertension. Our studies are the first to demonstrate that both C3a and C5a contribute to placental ischemia–induced hypertension, and inhibiting both receptors was no more effective than inhibiting each receptor alone.

By design, multiple inflammatory mediators can be evoked by any given perturbation, thus promoting survival of the organism but also contributing to difficulty in treating inflammatory disease. If the action or synthesis of one mediator (i.e., C3a or C5a) is prevented, another mediator may assume a primary role in uncontrolled inflammation. Our studies, and those of others, suggest that increased inflammation in pre-eclampsia involves cytokines, T cells, autoantibodies, and complement, along with pro- and antiangiogenic factors (LaMarca et al., 2013). This complex interplay of mediators suggests that therapy for pregnancy-induced hypertension will be a challenge similar to treatment of general inflammatory disease.

Increasing evidence supports a role for angiogenic imbalance in pregnancy-induced hypertension (Gilbert et al., 2012d). Our current studies demonstrated a decrease in circulating free VEGF but no increase in soluble fms-like tyrosine kinase-1 in the RUPP model. Further, neither C3aRA nor C5aRA affected the decrease in circulating VEGF concentrations, suggesting that this effect mechanistically precedes increased C3a and/or C5a action or that VEGF mediates hypertension via a parallel pathway. In the RUPP model, decreased VEGF could also potentially result in decreased complement control proteins, allowing increased complement activation as demonstrated in kidney endothelium (Mason et al., 2004; Kerr and Richards, 2012). Although a recent study by Weissgerber et al. (2014) questions the validity of the enzyme-linked immunosorbent assay for measurement of VEGF in rat plasma and serum, our previous studies have reported decreased angiogenic potential via endothelial tube formation assays in RUPP compared with normal pregnant controls (Gilbert et al., 2012b; Bauer et al., 2013). Clearly, a re-evaluation of the methodology for assessing angiogenic factors in the rat circulation is needed, with additional studies to understand the relationship between angiogenic

![Fig. 5. The C3aRA prevents increased MAP induced by C3a peptide in pregnant (GD 19) and nonpregnant females. C3a peptide increased MAP in GD 19 animals or nonpregnant females. The C3aRA did not increase MAP but inhibited the C3a peptide–induced increase in MAP. Values represent mean ± S.E. of percent increase in MAP in 4–8 animals per treatment group. *P < 0.05 versus C3a peptide injection alone.](image)

![Fig. 6. The C5aRA, but not the C3aRA, attenuates numbers of circulating neutrophils. Sham or RUPP animals were treated with Veh, C3aRA, or C5aRA from GD 14–18. A significant decrease in circulating neutrophils occurred with C5aRA treatment. Values represent mean ± S.E. of circulating neutrophils measured on GD 19. **P < 0.05 for C5aRA effect by analysis of variance.](image)
imbalance and complement activation/control proteins following placental ischemia. Both endothelial dysfunction and increased heart rate may contribute to cardiovascular abnormalities observed in pre-eclampsia and the RUPP rat model (Gilbert et al., 2012e). The C5aRA prevented endothelial dysfunction and increased heart rate associated with RUPP hypertension, suggesting that C5a substantially contributes to both in the RUPP model. We have previously shown that C5a has positive chronotropic effects on isolated male guinea pig atria (Regal, 1985). Thus, it is possible that C5aRA prevents a direct action of C5a on cardiomyocytes to increase heart rate in the RUPP model. Alternatively, C5aRA treatment may decrease sympathetic tone reportedly elevated in RUPP rats (Hines et al., 2007). However, the relevance of this to cardiovascular function in pre-eclampsia remains unclear (Greenwood et al., 2001). C5aRA also decreased circulating neutrophils in our study, consistent with recent data indicating that C5a stimulates production of granulocyte colony-stimulating factor (Bosmann et al., 2013), a substance known to play a role in regulating the number of neutrophils in circulation. C5a is also a potent neutrophil activator. The difficulty in detecting increases in C5a in circulation may be due to binding of any C5a generated in the circulation to the very-high-affinity receptor for C5a on neutrophils. However, our data demonstrate no evidence that the RUPP procedure nor the C3aRA or C5aRA results in neutrophil activation with resultant pulmonary sequestration. Our preliminary studies indicate that depletion of neutrophils also attenuates placental ischemia–induced hypertension (Lillegard et al., 2013a), suggesting that C5aRA could be limiting placental ischemia–induced hypertension by a neutrophil-dependent effect.

Clearly, a limitation of our study lies in inherent limitations of receptor antagonists. PMX53, the C5aRA chosen for this study, has been used in numerous animal models in both mice and rats to assess the importance of C5a in mediating a response through the C5a receptor (CD88; C5aR; C5aR1). It is important to recognize that C5a can interact with another receptor (C5L2; C5aR2), but PMX53 does not alter C5a action at this second C5a receptor (Klos et al., 2013). Both the C5aR and C5L2 mediate production of granulocyte colony-stimulating factor by C5b (Bosmann et al., 2013), and C5aR and C5L2 can form heteromers to regulate C5a function, with heteromer formation being inhibited by C5aRA (Croker et al., 2013). Our studies do not provide information regarding the importance of C5L2 or the cell or tissue location of the important C5aR for mediating hypertension. Further studies are needed to investigate these possibilities.

Both C3a and C5a have distinct acute hemodynamic effects in the anesthetized rat, with C3a increasing blood pressure transiently and C5a causing a more prolonged decrease in blood pressure (Proctor et al., 2009). In the guinea pig, we previously demonstrated that C5a increases blood pressure via thromboxane and the acute increase in blood pressure is dependent on WBCs and platelets (Fraser and Regal, 1990). Vascular reactivity to agonists can vary during pregnancy when compared with the nonpregnant state (Paller, 1987), but our current studies indicate that a pregnant rat reacts to C3a peptide with a similar acute pressor response as a nonpregnant rat (Proctor et al., 2006). The C3aRA prevents the increase in blood pressure, indicating that it is an effective antagonist of the C3a receptor (C3aR) in the pregnant and nonpregnant rat. The reduction in circulating C3a following administration of the C3aRA SB290157 suggests that it has other effects and may exert its inhibitory effect on placental ischemia–induced hypertension by non-C3aR actions, such as interfering with generation of C5a or complement activation in general. SB290157 in vitro has demonstrated high efficacy and specificity for the C3aR in rat and human cells, and it does not disrupt C5a-mediated cellular responses in vitro (Ames et al., 2001). However, Proctor et al. (2004) noted that SB290157 in vivo caused an acute transient increase in blood pressure and decrease in circulating neutrophils with intravenous injection, suggesting that it was also acting as a C3aR agonist. They concluded that the favorable effect of SB290157 in intestinal ischemia/reperfusion was likely due to its agonist action on neutrophils rather than its antagonism of C3aR (Wu et al., 2013). Mathieu et al. (2005) also described agonist activity of SB290157 in systems with high C3aR density, and others observed similar agonist properties in Chinese hamster
ovary cells and human U937 cells (Scully et al., 2010). In our study, the most perplexing limitation of the C3αRA was the fact that at 5 mg/kg it inhibited the RUPP-induced increase in C3α itself, and an explanation for this is not readily apparent. These data temper conclusions regarding the importance of C3α in our studies and suggest that the C3αRA is affecting hypertension by both C3α receptor and non-receptor pathways. In addition, our studies temper a conclusive role for C3αR in hypertension and proteinuria in pregnancy following adoptive transfer of angiotensin II type 1 receptor into third-trimester mice (Wang et al., 2012), in which doses up to 30 mg/kg per day of SB290157 were used to provide evidence for an important role of C3α. In our studies, the C3αRA SB290157 definitely inhibits increases in blood pressure following either C3α administration or placental ischemia, suggesting that C3α is an important mediator of placental ischemia-induced hypertension. However, non-C3αR effects of SB290157 may also be operating in vivo to reduce placental ischemia-induced hypertension.

In a recently published case report (Burwick and Feinberg, 2013), ecuclizumab, an antibody to C5, favorably extended pregnancy in a woman with severe pre-eclampsia. Whether ecuclizumab was effective in prolonging pregnancy because of its ability to limit C5α or C5b-9 formation or both is unknown. However, our studies in the rat model suggest that ecuclizumab may attenuate the severity of pre-eclampsia in part through its ability to limit formation of C5a, and further studies are under way to evaluate this possibility. Our studies to date have also not addressed how complement is activated following placental ischemia or which pathway(s) of complement activation is leading to the increase in circulating C5α. In a pregnant mouse model, studies by Wang et al. (2012) indicate that infusion of autoantibodies to the angiotensin II type 1 receptor lead to complement activation and hypertension, so a role for autoantibodies in RUPP-induced complement activation is possible. In addition, future immunohistochemistry studies are warranted to determine the site of complement activation by determining if C3 deposition is occurring in the vasculature and/or placenta and is associated with the increased blood pressure seen following placental ischemia.

Overall, our studies suggest an important role for both C3aR and C5αR in mediating placental ischemia–induced hypertension. Differential effects of the C5α and C5α receptor antagonists on endothelial cell–dependent vascular relaxation, cardiovascular function, and circulating neutrophil count suggest that C5α contributes to hypertension by increasing heart rate and impairing endothelial-dependent relaxation of blood vessels, whereas the C3αRA likely affects placental ischemia–induced hypertension by both C3αR and non-C3αR pathways. Previous studies of others have also demonstrated an important role for angiotensin II type 1 receptor agonistic autoantibodies, lymphocytes, endothelin, interleukin-10, interleukin-6, tumor necrosis factor, and angiogenic imbalance in placental ischemia–induced hypertension, with partial attenuation of the hypertension as each of these pathways is manipulated. The interrelationship of complement activation with these mediator pathways is unexplored, as is the mechanism of complement activation following placental ischemia. Clearly, a complex array of mediators and pathways, including the complement activation products C3α and C5α, are involved, and data suggest that therapeutic strategies for management of placental ischemia–induced hypertension will require a broad anti-inflammatory approach including therapy targeted at limiting the production or activity of complement activation products.

Acknowledgments

The authors thank Megan Strehlke and Courtney Bauer for excellent technical assistance in the completion of these studies.

Authorship Contributions

Participants in research design: Lillegard, R., Regal, Gilbert, J. Regal.
Conducted experiments: Lillegard, Loeks-Johnson, Opachic, Peterson, Bauer, Elmqquist, Gilbert, J. Regal.
Performed data analysis: R. Regal, J. Regal.
Wrote or contributed to the writing of the manuscript: Lillegard, Loeks-Johnson, Opachic, Peterson, Bauer, Elmqquist, R. Gilbert, J. Regal.

References

}


Address correspondence to: Dr. Jean F. Regal, Department of Biomedical Sciences, University of Minnesota Medical School Duluth, 1035 University Drive, Duluth, MN 55812. E-mail: jregal@d.umn.edu